MLTX vs. VTRS, ASND, RDY, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, and ROIV
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs. Its Competitors
Viatris (NASDAQ:VTRS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat MoonLake Immunotherapeutics' return on equity.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Viatris. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
In the previous week, Viatris and Viatris both had 5 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 0.90 beat Viatris' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
79.9% of Viatris shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Viatris currently has a consensus target price of $10.40, indicating a potential downside of 1.42%. MoonLake Immunotherapeutics has a consensus target price of $74.43, indicating a potential upside of 36.24%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Viatris.
Summary
MoonLake Immunotherapeutics beats Viatris on 10 of the 14 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 8/25/2025 by MarketBeat.com Staff
MarketBeat All Access